NASDAQ:SPRO - Spero Therapeutics Stock Price, Forecast & News

$8.89

-0.17 (-1.88 %)

(As of 01/17/2020 04:00 PM ET)

Add

Compare

Today's Range

$8.85

Now: $8.89▼

$9.24

50-Day Range

$8.89

MA: $10.46▼

$12.25

52-Week Range

$7.96

Now: $8.89▼

$14.48

Volume68,575 shs

Average Volume74,026 shs

Market Capitalization$170.07 million

P/E RatioN/A

Dividend YieldN/A

Beta1.98

Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections in the United States. Its product candidate includes SPR994, an oral carbapenem-class antibiotic to treat MDR gram-negative infections for adults; SPR741, which is in Phase Ib clinical trial to treat MDR gram-negative infections in the hospital setting; SPR206, an agent that is phase I clinical trial to disrupt the outer membrane of gram-negative bacteria; and SPR720, an oral antibiotic, which is in phase I clinical trial for the treatment of pulmonary non-tuberculous mycobacterial infections. Read More…

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:SPRO

Previous Symbol

CUSIPN/A

CIK1701108

Webhttp://www.sperotherapeutics.com/

Phone857-242-1600

Debt

Debt-to-Equity Ratio0.04

Current Ratio6.90

Quick Ratio6.90

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$3.97 million

Price / Sales42.84

Cash FlowN/A

Price / Cash FlowN/A

Book Value$6.73 per share

Price / Book1.32

Profitability

EPS (Most Recent Fiscal Year)($2.60)

Net Income$-41,660,000.00

Net Margins-287.11%

Return on Equity-43.10%

Return on Assets-38.10%

Miscellaneous

Employees41

Outstanding Shares19,130,000

Market Cap$170.07 million

Next Earnings Date3/12/2020 (Estimated)

OptionableOptionable

Receive SPRO News and Ratings via Email

Sign-up to receive the latest news and ratings for SPRO and its competitors with MarketBeat's FREE daily newsletter.

A Rare Upcoming Change to Bitcoin Could Yield Profits of 2,752% (Ad)

Free Report: In a few months the Bitcoin network will undergo a major change that will make it more scarce than ever before. Historically, this event has been correlated to a major price increase.

Spero Therapeutics (NASDAQ:SPRO) Frequently Asked Questions

What is Spero Therapeutics' stock symbol?

Spero Therapeutics trades on the NASDAQ under the ticker symbol "SPRO."

How were Spero Therapeutics' earnings last quarter?

Spero Therapeutics Inc (NASDAQ:SPRO) posted its earnings results on Monday, November, 4th. The company reported ($0.95) earnings per share for the quarter, missing the consensus estimate of ($0.85) by $0.10. The firm earned $4.64 million during the quarter, compared to analyst estimates of $2.03 million. Spero Therapeutics had a negative net margin of 287.11% and a negative return on equity of 43.10%. View Spero Therapeutics' Earnings History.

When is Spero Therapeutics' next earnings date?

Spero Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, March 12th 2020. View Earnings Estimates for Spero Therapeutics.

What price target have analysts set for SPRO?

5 brokerages have issued 1-year price objectives for Spero Therapeutics' shares. Their forecasts range from $20.00 to $35.00. On average, they expect Spero Therapeutics' share price to reach $27.33 in the next twelve months. This suggests a possible upside of 207.5% from the stock's current price. View Analyst Price Targets for Spero Therapeutics.

What is the consensus analysts' recommendation for Spero Therapeutics?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Spero Therapeutics in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Spero Therapeutics.

What are Wall Street analysts saying about Spero Therapeutics stock?

Here are some recent quotes from research analysts about Spero Therapeutics stock:

1. According to Zacks Investment Research, "Spero Therapeutics Inc. is a multi-asset, clinical-stage biopharmaceutical company. It focused on identifying, developing and commercializing novel treatments for multi-drug resistant bacterial infections. Spero Therapeutics Inc. is based in CAMBRIDGE, United States. " (9/12/2019)
2. HC Wainwright analysts commented, "916-3963, POS Risk-adj value Full value SPR994 (oral carbapenem) – cUTI 62% $22.87 $36.88 Shares outstanding 18,656 S/O as of SPR741 (IV potentiator) – MDR Gram (-) $3.22 $3.22 Current share price $9.23 Discount rate 14.5% SPR720 (oral treatment) – NTM $1.34 $1.34." (8/12/2019)
3. Cantor Fitzgerald analysts commented, ". Post a solid quarter of execution, we are reiterating our OW rating and 12-month price target of $27 for SPRO shares. As the company advances its pipeline toward commercialization, we think upward earnings revisions and multiple expansion to levels not reflected in FactSet consensus expectations will drive SPRO’s stock higher. We also like the stock ahead of what we expect to be multiple positive data readouts for 2019+. Anticipated 2019 events include pharmacokinetic data from a lead-in cohort of 70 patients in 2H19 for SPR994 in the cUTI patient population, Phase 1 data for 1 data for SPR720." (5/9/2019)

Has Spero Therapeutics been receiving favorable news coverage?

Media headlines about SPRO stock have trended very positive recently, InfoTrie Sentiment Analysis reports. InfoTrie identifies positive and negative media coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Spero Therapeutics earned a news sentiment score of 3.4 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the company's share price in the next several days. View News Stories for Spero Therapeutics.

Are investors shorting Spero Therapeutics?

Spero Therapeutics saw a increase in short interest in the month of December. As of December 31st, there was short interest totalling 377,500 shares, an increase of 6.2% from the December 15th total of 355,600 shares. Based on an average trading volume of 50,500 shares, the short-interest ratio is currently 7.5 days. Currently, 3.1% of the shares of the stock are short sold. View Spero Therapeutics' Current Options Chain.

Who are some of Spero Therapeutics' key competitors?

Some companies that are related to Spero Therapeutics include Processa Pharmaceuticals (PCSA), Flexion Therapeutics (FLXN), Cara Therapeutics (CARA), AC Immune (ACIU), Axovant Sciences (AXON), TherapeuticsMD (TXMD), Emisphere Technologies (EMIS), Morphic (MORF), Prothena (PRTA), Crinetics Pharmaceuticals (CRNX), Kura Oncology (KURA), MacroGenics (MGNX), Akero Therapeutics (AKRO), Magenta Therapeutics (MGTA) and Kadmon (KDMN).

What other stocks do shareholders of Spero Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Spero Therapeutics investors own include Catalyst Pharmaceuticals (CPRX), Crispr Therapeutics (CRSP), Fate Therapeutics (FATE), Rigel Pharmaceuticals (RIGL), Allena Pharmaceuticals (ALNA), Amicus Therapeutics (FOLD), Progenics Pharmaceuticals (PGNX), Exelixis (EXEL), Immunomedics (IMMU) and Karyopharm Therapeutics (KPTI).

Who are Spero Therapeutics' key executives?

Spero Therapeutics' management team includes the folowing people:

Mr. Ankit Mahadevia M.D., MBA, Co-Founder, CEO, Pres & Director (Age 38)
Mr. Joel D. Sendek, CFO, Treasurer & Sec. (Age 52)
Ms. Cristina Larkin, Chief Operating Officer (Age 49)
Dr. Thomas R. Parr Jr., Chief Scientific Officer (Age 65)
Ms. Sharon Klahre, Director of Investor Relations

When did Spero Therapeutics IPO?

(SPRO) raised $75 million in an initial public offering (IPO) on Thursday, November 2nd 2017. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch, Cowen and Stifel served as the underwriters for the IPO and Oppenheimer & Co. was co-manager.

How do I buy shares of Spero Therapeutics?

Shares of SPRO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Spero Therapeutics' stock price today?

One share of SPRO stock can currently be purchased for approximately $8.89.

How big of a company is Spero Therapeutics?

Spero Therapeutics has a market capitalization of $170.07 million and generates $3.97 million in revenue each year. The company earns $-41,660,000.00 in net income (profit) each year or ($2.60) on an earnings per share basis. Spero Therapeutics employs 41 workers across the globe.View Additional Information About Spero Therapeutics.

What is Spero Therapeutics' official website?

The official website for Spero Therapeutics is http://www.sperotherapeutics.com/.

How can I contact Spero Therapeutics?

Spero Therapeutics' mailing address is 675 Massachusetts Avenue 14th Floor, Cambridge MA, 02139. The company can be reached via phone at 857-242-1600 or via email at [email protected]

MarketBeat Community Rating for Spero Therapeutics (NASDAQ SPRO)

Community Ranking:		2.6 out of 5 ( )
Outperform Votes:		146 (Vote Outperform)
Underperform Votes:		136 (Vote Underperform)
Total Votes:		282

MarketBeat's community ratings are surveys of what our community members think about Spero Therapeutics and other stocks. Vote "Outperform" if you believe SPRO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SPRO will underperform the S&P 500 over the long term. You may vote once every thirty days.

This page was last updated on 1/18/2020 by MarketBeat.com Staff

Featured Article: What does the Producer Price Index (PPI) tell investors?

Your Ultimate Investing Toolkit

Just $1.00 for your first month.